Mary Kate Fan
Adult Health · Live Oak, TXNPI 1467844795
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AstraZeneca at 41.4% of the total. Reporting peaked in 2021 at $1,149 and has fallen 78.1% since, to $252 in 2025.
Across 143 payments — averaging $29.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$937
- Novartis$265
- CSL Behring$168
- Sanofi$161
- Kaleo, Inc.$153
- plus $768 from 11 others
Across 2 payments — averaging $1554.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$3K
What the payments were for
- Food & beverage$4,181100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $1,729 |
| GSK | 40 | $937 |
| Novartis | 11 | $265 |
| CSL Behring | 7 | $168 |
| Sanofi | 3 | $161 |
| Kaleo, Inc. | 6 | $153 |
| Genentech USA, Inc. | 4 | $112 |
| Alk-abello, Inc | 6 | $110 |
| Phadia US Inc. | 5 | $106 |
| Optinose US, Inc. | 5 | $97 |
| Amgen | 4 | $94 |
| Boehringer Ingelheim | 4 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Sanofi-aventis U.S. LLC | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Octapharma USA, Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,181 in reported general payments places this provider in the 85th percentile of 933 adult health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 41 | $1,398 |
| Fluticasone Propionate | 32 | $564 |
| Levocetirizine Dihydrochloride | 27 | $309 |
| Montelukast Sodium | 24 | $257 |
Paid to pharmacies, not to this prescriber.
Other adult health in Live Oak
- Misty SheddAllen$863K
- Melodie YoungDallas$700K
- Cynthia BedellPlano$168K
- Elizabeth Wedberg SivamAustin$71K
- Mary SalazarSan Antonio$68K
- Eric KlappholzDallas$44K
- Christin TouchetKingwood$43K
- Yulia LyuboslavskyAustin$36K
- Meghan MurphyAustin$29K
- Sandra CareyGrapevine$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.